FDA Rejects Approval of Another Diet Drug, Qnexa

Qnexa, a combination of phentermine and topiramate, has not been granted approval by the FDA, according to a New York Times report. Earlier this month the FDA refused approval for another diet drug, lorcaserin.

According to the report the agency has asked Vivus, Qnexa's developer, "to provide a thorough evaluation of the drug's potential for causing birth defects and heart problems." In a statement on its website, Vivus said that new studies may be required if the FDA's concerns are not addressed by existing data, which it plans to submit by year's end.

Link